 Home > Active Ingredient News > Antitumor Therapy > Liver Cancer: Response to Lenvatinib (Lenvatinib) Initial Treatment is a Prognostic Indicator for Lenvatinib (LEN) + Transarterial Chemoembolization (LEN-TACE) Sequential Therapy

Liver Cancer: Response to Lenvatinib (Lenvatinib) Initial Treatment is a Prognostic Indicator for Lenvatinib (LEN) + Transarterial Chemoembolization (LEN-TACE) Sequential Therapy

 Last Update: 2022-03-05
 Source: Internet
 Author: User

Tags

new host 1

electrolyte recovery plus

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Data on the benefit of sequential lenvatinib plus transarterial chemoembolization (LEN-TACE) for unresectable hepatocellular carcinoma (u-HCC) are limited
.

Therefore, a study was recently published in the journal Liver Cancer, mainly to compare the efficacy and safety of LEN-TRAE sequential therapy with LEN monotherapy in patients with unresectable hepatocellular carcinoma (u-HCC), and to explore the impact Factors of deep response to LEN-TRAE sequential therapy

Data on the benefit of sequential lenvatinib plus transarterial chemoembolization (LEN-TACE) for unresectable hepatocellular carcinoma (u-HCC) are limited

The study was a multicenter cohort study of 247 u-HCC patients treated with LEN between 2018 and 2020
.

Propensity score matching (PSM) identified 63 matched patients with well-balanced characteristics

The study was a multicenter cohort study of 247 u-HCC patients treated with LEN between 2018 and 2020

During the study period, 247 u-HCC patients received LEN

OS and PFS in all patients and in the PSM cohort

The median follow-up for the PSM cohort was 15.
6 months
.

Median OS was 31.

The median follow-up for the PSM cohort was 15.

According to mRECIST criteria, the proportion of patients with CR, PR, SD, and PD after 8 weeks of TACE treatment in the LEN-TACE group were 20.

The most common AEs of any grade in the LEN-TACE arm were fatigue (47.
6%), hypertension (46.
0%), and decreased appetite (42.
9%)
.

The most common ≥ grade 3 AE was hypertension (11.

The most common AEs of any grade in the LEN-TACE arm were fatigue (47.

In the LEN-TACE group, the median ALBI scores of LEN before administration, 3 months after administration, before TACE, and 2 months after TACE were -2.
38, -2.
30, -2.
26, and -2.
20, respectively, with no statistical difference.
meaning .

In the LEN-TACE group, the median ALBI scores of LEN before administration, 3 months after administration, before TACE, and 2 months after TACE were -2.

38, -2.

Multivariate analysis showed that OS was independently associated with mALBI grade 1+2a (P=0.
006), MVI-Vp0 (P<0.
001), and addition of TACE (P<0.
001); while RFS was associated with mALBI grade 1+2a (P=0.
007) was independently associated with the addition of TACE (P=0.
023)
.

In the LEN-TACE arm, 23 (36.
5%) patients achieved deep responses
.
The median OS of patients who achieved deep response was not reached, and the median OS of patients who did not achieve was 26.
5 months (19.
5-31.
3 months), which was statistically significant (P=0.
037)
.
In addition, the median PFS was 23.
3 (8.
7-29.
3) months for patients with deep responses and 10.
8 (7.
2-14.
3) months for those who did not (P=0.
037)
.
In the LEN-TACE arm, 23 (36.
5%) patients achieved deep responses
.
The median OS of patients who achieved deep response was not reached, and the median OS of patients who did not achieve was 26.
5 months (19.
5-31.
3 months), which was statistically significant (P=0.
037)
.
In addition, the median PFS was 23.
3 (8.
7-29.
3) months for patients with deep responses and 10.
8 (7.
2-14.
3) months for those who did not (P=0.
037)
.

Multivariate analysis showed that deep response was independently associated with the outcome of initial tumor response to LEN as assessed by mRECIST criteria: PR (odds ratio: 13.
753, 95% CI: 0.
408-1.
323, P<0.
001)
.

In this study, a total of 12 patients (19.
0%) achieved CR with sequential LEN-TACE treatment, of which 2 patients underwent conversion surgery
.
The median follow-up for CR patients was 17.
4 months
.
CR patients have a good prognosis, with a 1-year overall survival rate (OSR) of 100% and a 2-year OSR of 87.
5%)
.
New lesions were found in 5 cases; progression-free survival was 83.
3% at 3 months, 75.
0% at 6 months, and 58.
3% at 12 months
.

Taken together, these studies suggest that in u-HCC patients who respond to initial LEN therapy, sequential LEN-TACE therapy may provide more clinical benefit than LEN monotherapy
.
Objective response to initial LEN therapy as assessed by mRECIST was an independent factor influencing the depth of response .

Studies have shown that in u-HCC patients who respond to initial LEN therapy, sequential LEN-TACE therapy may provide more clinical benefit than LEN monotherapy
.
Objective response to initial LEN therapy as assessed by mRECIST affects the depth of sequential LEN-TACE therapy .
Studies suggest that in u-HCC patients who respond to initial LEN therapy, sequential LEN-TACE therapy may provide more than LEN monotherapy clinical benefit
.
Objective response to initial LEN therapy as assessed by mRECIST was an independent factor influencing the depth of response .

Original source:

Kuroda H, Oikawa T, Ninomiya M, et al.
Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy.
Liver Cancer , DOI: 10.
1159/000522424.
Published online: February 15, 2022.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.